A citation-based method for searching scientific literature

Maura L Furey, Ashish Khanna, Elana M Hoffman, Wayne C Drevets. Neuropsychopharmacology 2010
Times Cited: 77







List of co-cited articles
671 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity




A cholinergic-adrenergic hypothesis of mania and depression.
D S Janowsky, M K el-Yousef, J M Davis, H J Sekerke. Lancet 1972
852
31

Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses.
Bhavya Voleti, Andrea Navarria, Rong-Jian Liu, Mounira Banasr, Nanxin Li, Rose Terwilliger, Gerard Sanacora, Tore Eid, George Aghajanian, Ronald S Duman. Biol Psychiatry 2013
186
28

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Carlos A Zarate, Jaskaran B Singh, Paul J Carlson, Nancy E Brutsche, Rezvan Ameli, David A Luckenbaugh, Dennis S Charney, Husseini K Manji. Arch Gen Psychiatry 2006
27

Antidepressant effects of ketamine in depressed patients.
R M Berman, A Cappiello, A Anand, D A Oren, G R Heninger, D S Charney, J H Krystal. Biol Psychiatry 2000
25

mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists.
Nanxin Li, Boyoung Lee, Rong-Jian Liu, Mounira Banasr, Jason M Dwyer, Masaaki Iwata, Xiao-Yuan Li, George Aghajanian, Ronald S Duman. Science 2010
24

The effects of scopolamine on sleep and mood in depressed patients with a history of alcoholism and a normal comparison group.
J C Gillin, L Sutton, C Ruiz, D Darko, S Golshan, S C Risch, D Janowsky. Biol Psychiatry 1991
57
29

Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review.
Wayne C Drevets, Carlos A Zarate, Maura L Furey. Biol Psychiatry 2013
114
22

Baseline mood-state measures as predictors of antidepressant response to scopolamine.
Maura L Furey, Allison C Nugent, Andrew M Speer, David A Luckenbaugh, Elana M Hoffman, Erica Frankel, Wayne C Drevets, Carlos A Zarate. Psychiatry Res 2012
27
51

A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Nancy Diazgranados, Lobna Ibrahim, Nancy E Brutsche, Andrew Newberg, Phillip Kronstein, Sami Khalife, William A Kammerer, Zenaide Quezado, David A Luckenbaugh, Giacomo Salvadore,[...]. Arch Gen Psychiatry 2010
659
16

Oral scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled study.
Danial Khajavi, Mehdi Farokhnia, Amirhossein Modabbernia, Mandana Ashrafi, Seyed-Hesammedin Abbasi, Mina Tabrizi, Shahin Akhondzadeh. J Clin Psychiatry 2012
68
19

NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses.
Anita E Autry, Megumi Adachi, Elena Nosyreva, Elisa S Na, Maarten F Los, Peng-fei Cheng, Ege T Kavalali, Lisa M Monteggia. Nature 2011
15

M1 and m2 muscarinic receptor subtypes regulate antidepressant-like effects of the rapidly acting antidepressant scopolamine.
J M Witkin, C Overshiner, X Li, J T Catlow, G N Wishart, D A Schober, B A Heinz, A Nikolayev, V V Tolstikov, W H Anderson,[...]. J Pharmacol Exp Ther 2014
72
16

Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder.
Dara M Cannon, Richard E Carson, Allison C Nugent, William C Eckelman, Dale O Kiesewetter, Joan Williams, Denise Rollis, Michele Drevets, Shilpa Gandhi, Gerardo Solorio,[...]. Arch Gen Psychiatry 2006
69
15

Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure.
Nanxin Li, Rong-Jian Liu, Jason M Dwyer, Mounira Banasr, Boyoung Lee, Hyeon Son, Xiao-Yuan Li, George Aghajanian, Ronald S Duman. Biol Psychiatry 2011
738
14


Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Madhukar H Trivedi, A John Rush, Stephen R Wisniewski, Andrew A Nierenberg, Diane Warden, Louise Ritz, Grayson Norquist, Robert H Howland, Barry Lebowitz, Patrick J McGrath,[...]. Am J Psychiatry 2006
12

Association of the muscarinic cholinergic 2 receptor (CHRM2) gene with major depression in women.
David E Comings, Sujihan Wu, M Rostamkhani, Matt McGue, William G Iacono, James P MacMurray. Am J Med Genet 2002
68
14

Cholinergic reversal of manic symptoms.
D S Janowsky, M K el-Yousef, J M Davis, B Hubbard, H J Sekerke. Lancet 1972
73
13

The effects of acute scopolamine in geriatric depression.
P A Newhouse, T Sunderland, P N Tariot, H Weingartner, K Thompson, A M Mellow, R M Cohen, D L Murphy. Arch Gen Psychiatry 1988
50
20


GABA interneurons mediate the rapid antidepressant-like effects of scopolamine.
Eric S Wohleb, Min Wu, Danielle M Gerhard, Seth R Taylor, Marina R Picciotto, Meenakshi Alreja, Ronald S Duman. J Clin Invest 2016
83
12


Rapid antidepressant actions of scopolamine: Role of medial prefrontal cortex and M1-subtype muscarinic acetylcholine receptors.
Andrea Navarria, Eric S Wohleb, Bhavya Voleti, Kristie T Ota, Sophie Dutheil, Ashley E Lepack, Jason M Dwyer, Manabu Fuchikami, Astrid Becker, Filippo Drago,[...]. Neurobiol Dis 2015
79
11

Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Nancy DiazGranados, Lobna A Ibrahim, Nancy E Brutsche, Rezvan Ameli, Ioline D Henter, David A Luckenbaugh, Rodrigo Machado-Vieira, Carlos A Zarate. J Clin Psychiatry 2010
403
10



Evidence of common and specific genetic effects: association of the muscarinic acetylcholine receptor M2 (CHRM2) gene with alcohol dependence and major depressive syndrome.
Jen C Wang, Anthony L Hinrichs, Heather Stock, John Budde, Rebecca Allen, Sarah Bertelsen, Jennifer M Kwon, William Wu, Danielle M Dick, John Rice,[...]. Hum Mol Genet 2004
217
10

Is cholinergic sensitivity a genetic marker for the affective disorders?
D S Janowsky, D H Overstreet, J I Nurnberger. Am J Med Genet 1994
100
10

No antidepressant effect of biperiden compared with placebo in depression: a double-blind 6-week clinical trial.
J C Gillin, J Lauriello, J R Kelsoe, M Rapaport, S Golshan, W M Kenny, L Sutton. Psychiatry Res 1995
25
32

Acetylcholine and depression.
D S Janowsky, M K el-Yousef, J M Davis. Psychosom Med 1974
137
10

Potential of pretreatment neural activity in the visual cortex during emotional processing to predict treatment response to scopolamine in major depressive disorder.
Maura L Furey, Wayne C Drevets, Elana M Hoffman, Erica Frankel, Andrew M Speer, Carlos A Zarate. JAMA Psychiatry 2013
69
11

Cholinergic signaling in the hippocampus regulates social stress resilience and anxiety- and depression-like behavior.
Yann S Mineur, Adetokunbo Obayemi, Mattis B Wigestrand, Gianna M Fote, Cali A Calarco, Alice M Li, Marina R Picciotto. Proc Natl Acad Sci U S A 2013
226
10

Antidepressant treatment history as a predictor of response to scopolamine: clinical implications.
Jessica S Ellis, Carlos A Zarate, David A Luckenbaugh, Maura L Furey. J Affect Disord 2014
20
40

Activity-Dependent Brain-Derived Neurotrophic Factor Release Is Required for the Rapid Antidepressant Actions of Scopolamine.
Sriparna Ghosal, Eunyoung Bang, Wenzhu Yue, Brendan D Hare, Ashley E Lepack, Matthew J Girgenti, Ronald S Duman. Biol Psychiatry 2018
68
11

Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.
Sungho Maeng, Carlos A Zarate, Jing Du, Robert J Schloesser, Joseph McCammon, Guang Chen, Husseini K Manji. Biol Psychiatry 2008
832
9


Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine.
Giacomo Salvadore, Brian R Cornwell, Fabio Sambataro, David Latov, Veronica Colon-Rosario, Frederick Carver, Tom Holroyd, Nancy DiazGranados, Rodrigo Machado-Vieira, Christian Grillon,[...]. Neuropsychopharmacology 2010
140
9

Genetic variation in cholinergic muscarinic-2 receptor gene modulates M2 receptor binding in vivo and accounts for reduced binding in bipolar disorder.
D M Cannon, J K Klaver, S K Gandhi, G Solorio, S A Peck, K Erickson, N Akula, J Savitz, W C Eckelman, M L Furey,[...]. Mol Psychiatry 2011
41
17

Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex.
Rong-Jian Liu, Francis S Lee, Xiao-Yuan Li, Francis Bambico, Ronald S Duman, George K Aghajanian. Biol Psychiatry 2012
271
9


The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).
Ronald C Kessler, Patricia Berglund, Olga Demler, Robert Jin, Doreen Koretz, Kathleen R Merikangas, A John Rush, Ellen E Walters, Philip S Wang. JAMA 2003
9


Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication.
Ronald C Kessler, Wai Tat Chiu, Olga Demler, Kathleen R Merikangas, Ellen E Walters. Arch Gen Psychiatry 2005
9

Synaptic dysfunction in depression: potential therapeutic targets.
Ronald S Duman, George K Aghajanian. Science 2012
785
9

BDNF release is required for the behavioral actions of ketamine.
Ashley E Lepack, Manabu Fuchikami, Jason M Dwyer, Mounira Banasr, Ronald S Duman. Int J Neuropsychopharmacol 2014
223
9

Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine.
Giacomo Salvadore, Brian R Cornwell, Veronica Colon-Rosario, Richard Coppola, Christian Grillon, Carlos A Zarate, Husseini K Manji. Biol Psychiatry 2009
185
7


The effects of intrahippocampal scopolamine infusions on anxiety in rats as measured by the black-white box test.
J W Smythe, S Bhatnagar, D Murphy, C Timothy, B Costall. Brain Res Bull 1998
56
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.